NBSE earnings

Data show that Stealth Editors™ achieve ex vivo gene editing using simple synthetic reagents to harness the cell's own high-fidelity editing machineryData show that Stealth Editors™ do not elicit a cell-based immunity and promise a non-immunogenic in vivo solution Data show that Stealth Editors™ can be encapsulated via established lipid nanoparticle technologies promising a non-immunogenic delivery solution and a de-risked pathway to address therapeutic targets in the liverData featured in an oral presentation at the American Society of Gene & Cell Therapy ("ASGCT") 2023 Annual Meeting Company to present additional data showcasing gene editing capabilities of Stealth Editors™ throughout rema

Announced oral presentations at the American Society of Gene & Cell Therapy ("ASGCT") 26th Annual Meeting to take place on May 16-20, 2023 Company to present additional data showcasing gene editing capabilities at scientific conferences throughout remainder of 2023 PITTSBURGH, May 11, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ:NBSE) ("NeuBase" or the "Company"), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today reported its financial results for the three-month period ended March 31, 2023 and other recent developments. "To date in 2023, we have made steady progress advancing the development o

A single intravenous dose of NeuBase's Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescues splicing, restores chloride channel (Clcn1) function, and durably reverses myotonia in the HSALR modelMultiple subcutaneous doses also lead to molecular and functional rescue in the HSALR model demonstrating efficacy in a dose-dependent manner and potential feasibility of this patient-friendly administration routeCompany remains on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in 4Q CY2022NeuBase management to host a conference call and webcast tomorrow, March 14, at 8:00 a.m. EDT PITTSBURGH and CAMBRIDGE,

Extended cash runway into CY2023 following completion of an equity financing from leading healthcare investors generating $42.6 million in net proceeds; supports advancing the Company's lead program into the clinic and scaling of its precision genetic medicine pipelineCompleted acquisition of peptide-nucleic acid ("PNA") scaffold technologies, to expand the PATrOL™ platform capabilities and consolidate PNA intellectual propertyScheduled to host an R&D day on June 8th to present new preclinical data, updates on myotonic dystrophy type 1 (DM1) and Huntington's disease (HD) programs, and unveil a new program in oncology PITTSBURGH, May 13, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc.

Recently demonstrated single-dose intravenous administration of a PATrOL™-enabled compound resolves the causal genetic defect in myotonic dystrophy type 1 (DM1) in transgenic animals; Company on course to move one program into clinical development in CY2022 Plans to host an R&D day in the first half of CY2021 to provide updates on platform innovations, the DM1 and Huntington's disease (HD) programs and pipeline expansion in high value indications Expects to complete consolidation of intellectual property in the space through acquisition of gene modulating technology from Vera Therapeutics in Q1 CY2021 PITTSBURGH, Feb. 11, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBS